<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2765">
  <stage>Registered</stage>
  <submitdate>12/05/2010</submitdate>
  <approvaldate>12/05/2010</approvaldate>
  <nctid>NCT01123707</nctid>
  <trial_identification>
    <studytitle>To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)</studytitle>
    <scientifictitle>A Multicenter, 52-week, Open-label Study to Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder</scientifictitle>
    <utrn />
    <trialacronym>ACES 257</trialacronym>
    <secondaryid>31-08-257</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Major Depressive Disorder (MDD)</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Aripiprazole/Escitalopram combination therapy

Experimental: Aripiprazole/Escitalopram combination therapy - 


Treatment: drugs: Aripiprazole/Escitalopram combination therapy
Aripiprazole/Escitalopram combination therapy: 3 mg/10 mg, 3 mg/20 mg, 6 mg/10 mg, 6 mg/20 mg, 12 mg/10 mg or 12 mg/20 mg

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety - based on the frequency and severity of AEs &amp; SAEs - The primary evaluation of safety will be through frequency and severity of adverse events (AEs), including serious AEs (SAEs), and discontinuations due to AEs.
In addition to AEs, safety variables examined in this study will include physical exams, vital signs, body weight, body mass index, clinical laboratory tests, electrocardiograms, the Abnormal Involuntary Movement Scale (AIMS), the Simpson Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), the Columbia-Suicide Severity Rating Scale (C-SSRS), and the Massachusetts General Hospital Sexual Functioning Inventory (MGH SFI).</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy - Evaluation of efficacy will include the Clinical Global Impressions Severity of Illness Scale (CGI-S) and the Patient Global Impressions of Severity Scale (PGI-S).
Outcome: The Sheehan Disability Scale (SDS), the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q - Short Form), and the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ). Responses to the Resource Utilization Form will be summarized appropriately to explore the impact of treatment on health care resources.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects who participated in Protocol 31-08-255, 31-08-256, or 31-08-263.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>66</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects with a current need for involuntary commitment or who have been hospitalized
             = 28 days of the Baseline Visit for the current major depressive episode.

          -  Subjects with a diagnosis of delirium, dementia, amnestic or other cognitive disorder,
             schizophrenia, schizoaffective disorder, or other psychotic disorder, Bipolar I or II
             disorder, Eating disorder (including anorexia nervosa or bulimia), obsessive
             compulsive disorder, panic disorder, or posttraumatic stress disorder.

          -  Subjects with a diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal
             or histrionic personality disorder.

          -  Subjects experiencing hallucinations, delusions, or any psychotic symptomatology in
             the current depressive episode.

          -  Subjects who have met DSM-IV-TR criteria for substance abuse in the past 6 months
             (prior to the Baseline Visit) and/or dependence up to and including the past 12 months
             (prior to the Baseline Visit), including alcohol and benzodiazepines, but excluding
             caffeine and nicotine. Subjects with two positive drug results for cocaine should be
             excluded from the study.

          -  Subjects with hypothyroidism or hyperthyroidism.

          -  Subjects with a significant risk of committing suicide based on history,
             investigator's judgment, and/or evaluation based on the C-SSRS

          -  Subjects who currently have clinically significant neurological, hepatic, renal,
             metabolic, hematological, immunological, cardiovascular, pulmonary, or
             gastrointestinal disorders.

          -  Subjects with insulin-dependent diabetes mellitus (IDDM).

          -  Subjects with epilepsy or significant history of seizure disorders, except for a
             single childhood febrile seizure, post-traumatic, etc.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>170</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital> - Everton Park</hospital>
    <postcode>4053 - Everton Park</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Jamejala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tartu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ostfildern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Gujarat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Catania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Siena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gwangju</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>DF</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This will be a multicenter, 52-week, open-label study designed to assess the safety and
      tolerability of an oral aripiprazole/escitalopram combination therapy in outpatients with
      major depressive disorder (MDD). Enrollment into the study will be from eligible subjects who
      have completed participation in Protocol 31-08-255, 31-08-256, or 31-08-263 ("rollover"
      subjects).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01123707</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>